Want to see PTCT full AI Analyst Report?
PTC Therapeutics (PTCT) Stock Forecast & Price Target
PTCT Analyst Ratings
Strong Buy
10Buy2Hold0Sell
Based on 12 analysts giving stock ratings to PTC Therapeutics in the past 3 months
PTCT Stock 12 Month Forecast
Average Price Target
$100.00▲(64.26% Upside)Based on 12 Wall Street analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $100.00 with a high forecast of $137.00 and a low forecast of $62.00. The average price target represents a 64.26% change from the last price of $60.88.
Past 12 Months12 Month ForecastJan2026Oct2026
High$137.00
Average$100.00
Low$62.00
Highest Price TargetHighest$137.00Average Price Target$100.00Lowest Price TargetLowest$62.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Eliana Merle | Barclays | $122 | buy | 100.39%Upside | Reiterated | 11/02/26 | ||
| Eric Joseph | Citi | $108→$109 | buy | 79.04%Upside | Reiterated | 11/02/26 | ||
| Brian Cheng | J.P. Morgan | $91→$92 | buy | 51.12%Upside | Reiterated | 11/02/26 | ||
| Joon Lee | UBS | $90 | buy | 47.83%Upside | Reiterated | 10/30/26 | ||
| Benjamin Burnett | Wells Fargo | $109→$112 | buy | 83.97%Upside | Reiterated | 10/30/26 | ||
| Joseph Thome | TD Cowen | $90→$95 | buy | 56.04%Upside | Reiterated | 10/30/26 | ||
| Tazeen Ahmad | Bank of America Securities | ― | buy | ― | Reiterated | 10/30/26 | ||
| Brian Abrahams | RBC Capital | $75→$77 | hold | 26.48%Upside | Reiterated | 10/29/26 | ||
| Kristen Kluska | Cantor Fitzgerald | $137 | buy | 125.03%Upside | Reiterated | 10/29/26 | ||
| Tiago Fauth | Raymond James | $108→$106 | buy | 74.11%Upside | Reiterated | 10/20/26 | ||
 Alex NackenoffNot Ranked | Truist Financial | $62 | hold | 1.84%Upside | Initiated | 10/16/26 | ||
| Basma Radwan | Leerink Partners | $70→$98 | buy | 60.97%Upside | Initiated | 09/14/26 | ||
| Judah Frommer | Morgan Stanley | $93→$104 | buy | 70.83%Upside | Reiterated | 07/31/26 | ||
| Paul Choi | Goldman Sachs | $70 | sell | 14.98%Upside | Reiterated | 07/30/26 | ||
| Faisal Khurshid | Jefferies | $76→$85 | buy | 39.62%Upside | Upgraded | 05/27/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Eliana Merle | 11/02/26 | $122 | buy | 100.39%Upside | Reiterated | Barclays | ||
| Eric Joseph | 11/02/26 | $108→$109 | buy | 79.04%Upside | Reiterated | Citi | ||
| Brian Cheng | 11/02/26 | $91→$92 | buy | 51.12%Upside | Reiterated | J.P. Morgan | ||
| Joon Lee | 10/30/26 | $90 | buy | 47.83%Upside | Reiterated | UBS | ||
| Benjamin Burnett | 10/30/26 | $109→$112 | buy | 83.97%Upside | Reiterated | Wells Fargo | ||
| Joseph Thome | 10/30/26 | $90→$95 | buy | 56.04%Upside | Reiterated | TD Cowen | ||
| Tazeen Ahmad | 10/30/26 | ― | buy | ― | Reiterated | Bank of America Securities | ||
| Brian Abrahams | 10/29/26 | $75→$77 | hold | 26.48%Upside | Reiterated | RBC Capital | ||
| Kristen Kluska | 10/29/26 | $137 | buy | 125.03%Upside | Reiterated | Cantor Fitzgerald | ||
| Tiago Fauth | 10/20/26 | $108→$106 | buy | 74.11%Upside | Reiterated | Raymond James | ||
| Alex NackenoffNot Ranked | 10/16/26 | $62 | hold | 1.84%Upside | Initiated | Truist Financial | ||
| Basma Radwan | 09/14/26 | $70→$98 | buy | 60.97%Upside | Initiated | Leerink Partners | ||
| Judah Frommer | 07/31/26 | $93→$104 | buy | 70.83%Upside | Reiterated | Morgan Stanley | ||
| Paul Choi | 07/30/26 | $70 | sell | 14.98%Upside | Reiterated | Goldman Sachs | ||
| Faisal Khurshid | 05/27/26 | $76→$85 | buy | 39.62%Upside | Upgraded | Jefferies |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering PTC Therapeutics
3 Months
Success Rate13/18 ratings generated profit
72%
Average Return
+14.92%
Copying Tiago Fauth's trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +14.92% per trade.
1 Year
Success Rate15/18 ratings generated profit
83%
Average Return
+46.16%
Copying Tiago Fauth's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +46.16% per trade.
2 Years
Success Rate23/27 ratings generated profit
85%
Average Return
+58.74%
Copying Sami Corwin's trades and holding each position for 2 Years would result in 85.19% of your transactions generating a profit, with an average return of +58.74% per trade.
PTCT Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 7 | 9 | 11 | 14 | 13 |
| Buy | 14 | 10 | 10 | 6 | 4 |
| Hold | 5 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 27 | 23 | 25 | 23 | 20 |
In the current month, PTCT has received 17 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. PTCT average Analyst price target in the past 3 months is 100.00.
PTCT Financial Forecast
High$0.90
Consensus$0.35
Low$-0.43
PTCT Earnings Forecast
Next quarter’s earnings estimate for PTCT is $0.35 with a range of -$0.43 to $0.90. The previous quarter’s EPS was -$0.62. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$348M
Consensus$330M
Low$303M
PTCT Sales Forecast
Next quarter’s sales forecast for PTCT is $329.60M with a range of $303.28M to $348.00M. The previous quarter’s sales results were $357.81M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
PTCT Stock Forecast FAQ
What is PTCT’s average 12-month price target, according to analysts?
Based on analyst ratings, PTC Therapeutics’s 12-month average price target is $100.00.
What is PTCT’s upside potential, based on the analysts’ average price target?
PTC Therapeutics has 64.26% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PTCT a Buy, Sell or Hold?
PTC Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.
What is PTC Therapeutics’s price target?
The average price target for PTC Therapeutics is $100.00. This is based on 12 12-month price targets, issued in the past 3 months. The highest analyst price target is $137.00, the lowest forecast is $62.00. The average price target represents a 64.26% increase from the current price of $60.88.
What do analysts say about PTC Therapeutics?
PTC Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Street analysts.
How can I buy shares of PTCT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
